Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vorinostat in Pediatric Drug Resistant Epilepsy
NCT03894826Phase 2Unknown
- Sponsor
- University of Calgary
- Start
- Dec 2018
- Primary completion
- Apr 2020
- Modality
- Covalent Small Molecules, Classical Binding Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vorinostat in epilepsy, sponsored by University of Calgary. Primary endpoints: Incidence of Treatment-Emergent Adverse Events at 84 days and Incidence of Drug Discontinuations due to Adverse Drug Reaction at 84 days. Status: unknown.
02
Drugs
vorinostat
03
Conditions
epilepsy
Beyond the preview
Go deeper on NCT03894826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03894826.